Look at the presentation from the last session about a month ago and please tell me what in the pipe has changed or further along so additional information can be added to what was presented. The one important thing I think ASTX could be more positive on the potential impact to revenue from an unknown generic. I think the street is starting to believe it the generic may not happen. So unless ASTX knows something no one else knows about a generic, discuss the risk but stop assuming an impact.
I think the recent runup could have something to do what KY posted recently:
"AZD3293 has just set up a trial to test this drug in Alzheimer patients. Prior to this, it was with healthy patients. This is the second large bio to increase trials of astx drugs. Also recall just a few weeks ago management increased shares, to be prepared for insider option exercise. Things are falling in place fast."